Non-epithelial tumours of stomach and intestine were described and termed as leomyomas because they possessed smooth muscle features when examined under light microscopy. Recently cell of origin of these tumourshave been identified as a pluripotential mesenchymal stem cell programmed to differentiate into the interstitial cells of Cajal. Gastrointestinal stromal tumours (GIST) is widely accepted term used for these tumours.
Introduction
Tumours of gastro-intestinal tract other than adenocarcinoma were described in early twentieth century. Historically, these lesions were classified as leiomyomas or leiomyosarcomas because they possessed smooth muscle features when examined under light microscopy. Raiford in 1931 described 3 cases of leomyoma out of 28 small intestinal tumors in a retrospective autopsy study at John Hopkins. 1 Similar observations were reported by others also. These were also known as Leiomyosarcornas or leiomyoblastomas. These were believed to arise from smooth muscles of gut wall. Mazur & Clark first introduced the term "Stromal Tumor" in 1983 to define a group of gastric mesenchymal tumors do not possess the ultrastructural and immunohistochemical _ features characteristic of smooth muscle differentiation, as are seen in leiomyomas. 1 With the advent of electron microscopy and immunohistochemistry, histologic criteria for the diagnosis of GIST has been determined as: A spindled and/or epitheloid mesenchymal tumor of the GIT with unequivocal KIT immunoreactivity. 2 Numerous studies have been carried out in recent years focusing mainly on molecular abnormalities, pathogenesis , diagnostic criteria & clinical therapy of GIST. The outcome is that, there are evidence based proposals regarding the diagnostic pathway, treatment plan & scheme of risk stratification of recurrence. However, information in some aspect is still lacking. This article aims to bridge this gap in knowledge & put forward all the available recommendations in a concise manner to lead the way for a future plan of management of GIST. of uncertain malignant potential and, thus, are not reported to national cancer registries were important contributing factors 3 . GIST comprise <1 % of all GI tumors but they are the most common mesenchymal tumors of the GI tract. Mucciarini et al calculated the age-adjusted incidence rate of GIST to be 6.6/million/year in a series of 124 cases 4 . In another series of 114 cases, Tryggvason et al calculated an annual incidence rate of 1.1 / 100,000 5 . Nilsson et al calculated an annual incidence rate of 14.5/million & a prevalence rate of 129/million in a series of 288 cases 3 . A study based on the US Surveillance, Epidemiology & End Result(SEER) registry data from 1992 to 2000 found the age adjusted yearly incidence of GIST to be 6.8/million 6 . Who are affected by GIST: GISTs are rare before the age of 40 years & very rare in children. They show a slight male predominance. In a series of 32 cases, Arolfo et al found the mean age of patients with GIST were 63. 7 years with a range of 40-90 years & incidence was slightly higher in males(56%)7. In another series of 1765 cases, Miettinen, Sobin et al found that the GIST has a slight male predominance (55%) with a median age of 63 years & tumor occurrence rate of 2.7% before the age of 21 years & 9.1 % before 40 years 8 . Mucciarini et al found similar results with male predominance (53.2%) & median age of presentation of 69 years (range 30-90 years) 4 . GISTs in children are a distinct subset with strong predominance for girls, multifocal gastric location, and a wild-type phenotype. Lymph node metastasis and local recurrence to the gastric stump is common in this setting. The clinical behavior of pediatric GISTs appears more indolent, compared with adult GISTs 9 . Where does GIST occur: GISTs can occur anywhere in the Gastro Intestinal tract from the esophagus to the rectum. But the most common site is stomach as evidenced by all the large series of patients (Table I) .
Approximately 10-30% GISTs are overtly malignant in behavior 9 . The principle sites of metastases are liver (65%) & peritoneal cavity (21 %). Lymph node metastases are uncommon(6%). Sites of extraabdominal metastases are bone (6%) & lungs (2%) 10 .
Origin, Pathology and immunhistochemistry :
GISTs are usually circumscribed, highly vascular, soft and friable lesions. Larger tumours may ulcerate on the mucosa! or serosal surface. There may be areas of necrosis or degeneration. Microscopically there are three sub-groups; Spindle cell type, Epitheloid type and mixed variety having both.
Since the term GIST was introduced by Mazur and Clark in 1983, laboratory investigations aimed at the subcellular and molecular levels have demonstrated that GISTs do not possess the ultrastructural and immunohistochemical features characteristic of smooth muscle differentiation, as are seen in leiomyomas and leiomyosarcomas. Therefore, GISTs are believed to arise from another mesenchymal derivative such as the progenitors of spindle and epithelioid cells. According to the work of Kindblom and associates reported in 1998, the actual cell of origin of GISTs is a pluripotential mesenchymal stem cell programmed to differentiate into the interstitial cell of Cajal. These are GI pacemaker cells and are largely responsible for initiating and coordinating GI motility. Perhaps the most critical development that distinguished GISTs as a unique clinical entity was the discovery of c-kit proto-oncogene mutations in these tumors by Hirota and colleagues in 1998 5 . In another series of 906 cases of GIST of jejunum & ileum, GI bleeding is found to be the most common symptom-as in cases with stomach GIST. This was most often insidious bleeding with anemia and weakness. Twelve patients were known to have bleeding episodes (melaena & rarely hematemesis) severe enough to require transfusions 14 .
Acute abdomen prompting emergency surgery occurred in 131 patients. This included intestinal obstruction (n = 51 ), tumor rupture with intra abdominal hemorrhage (n=47), and appendicitis-like acute pain (n = 33).0ther clinical contexts for the discovery of tumor included evaluation of chronic abdominal pain (n=54) & pelvicmass (n=43). Symptoms such as pain, weight loss, and fever (n=22) were often associated with large and advanced tumors. Positron Emission Tomography: the value of PET is two-fold. Most GISTs appear to take up 18 FDG avidly and thus PET represents a very sensitive staging tool, capable of demonstrating the presence of metastatic disease that is not visible on CT. Secondly, if the patient has metastatic disease with a positive PET scan, and is going to receive treatment with imatinib, then PET will provide a rapid means of determining the responsiveness of the tumor to imatinib, showing response much earlier than response can be seen on CT.The disadvantages are that it is not widely available & may not detect tumors <2 cm diameter 23 . 
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Differential Diagnosis:
It is important to differentiate between GISTs, which constitute approximately 80% of GI mesenchymal tumors, and the less common GI non-epithelial neoplasms, leiomyoma, leiomyosarcoma (10-15% of mesenchymal tumors), schwannomas (5%), and other malignant disorders 26 .
Prediction of Tumor Behavior:
Unlike other GI malignancies, the behavior of GIST is difficult to predict based on histopathology alone. Many factors including tumor size, mitotic rate, tumor location, kinase mutational status and occurrence of tumor rupture have been proposed to be predictors of survival outcomes, but tumor size and mitotic rate are the two most widely accepted indices.
In 2001, the National Institutes of Health (NIH) in the USA developed by consensus scheme for predicting the risk of recurrence or metastasis of a surgically resected primary GIST (Table-V) . Previously patients with a ruptured tumor or multifocal peritoneal nodules at the time of resection of primary tumor have been treated with several conventional adjuvant chemotherapy without demonstrable benefit. However, a number of significant clinical issues remain. These include optimal disease risk stratification, length of adjuvant treatment, optimal imatinib dose and timing of surgery.
Primary Disease: Surgery:
Surgical resection has been the mainstay of therapy for GIST from pre lmatinib era. The primary goal of surgery is complete resection of disease without tumor rupture aiming for a macroscopically complete resection with negative microscopic margins. Unlike intestinal adenocarcinomas, GIST rarely metastasizes to lymph nodes, and thus lymphadenectomy is seldom warranted. Achieving negative pathologic margins of resection is not difficult because GIST tend to hang from, not diffusely infiltrate, the organ of origin. Consequently wedge resection of the stomach or segmental resection of the intestine provides adequate therapy and wide resection has no known benefit 29 -32 . An adequate cancer margin is considered to be 2 cm but this is not always possible. The surgeon should aim to preserve function, but not at the expense of R 0 resection. In cases where adjacent organs are involved, en bloc resection is recommended whenever possible 33 · 34 . Extensive surgery is occasionally required for large or poorly located tumors, such as those near the gastro esophageal junction, peri ampullary region, or lower rectum. These tumors should also be carefully handled to avoid tumor rupture, which leads to a very high risk of intra-abdominal dissemination and recurrence 35 . The 5-year overall survival rate after complete resection of GISTs is 50%-65% 10 · 31 • 32 .
Adjuvant therapy:
The outcome of surgery alone has not been very satisfactory. In a recent analysis of 200 patients with GIST treated and followed prospectively at the Memorial Sloan-Kettering Cancer Center (MSKCC), 80 patients with primary tumor without metastasis underwent complete gross surgical resection, and their 5-year disease-specific survival rate was 54%. At a median follow up of 24 months, 32 of these 80 patients (40%) developed recurrent disease. Patients with tumors >10 cm had a disease-specific 5-year survival of only 20% after resection.U'" Investigators at the M.D. Anderson Cancer Center (MDACC) have reported similar results with 60% of 122 patients presenting with recurrent disease within 2 years of primary tumor resection. ( 36 l The early results suggest that lmatinib increases recurrence-free survival and may be an effective treatment to prevent recurrence following primary surgery.
The American College of Surgeons Oncology Group (ACOSOG) Inter-group Adjuvant GIST Study Team undertook a randomized phase Ill, double-blind, placebo-controlled, multicenter trial (Z 9001 ), the aim of which was to assess the effectiveness of lmatinib as adjuvant therapy in patients who had undergone complete resection of primary GIST. In total, 708 patients who underwent complete gross resection of a primary GIST of at least 3 cm in size and expressing KIT were randomized in a double blind fashion to 1 year of lmatinib at 400 mg/day (n=359) or placebo (n=354). At a median follow-up of 19.7 months, 30 (8%) patients in the imatinib group and 70 (20%) in the placebo group had tumor recurrence or had died. lmatinib significantly improved recurrence-free survival compared with placebo (98% vs. 83% at 1 year) 37 . Based on these results, in 2008, imatinib was approved at a daily dose of 400 mg by the U.S. Food and Drug Administration (FDA) as adjuvant therapy for high-risk patients following complete surgical resection of GIST.
In 2009, the European Medicines Agency approved the use of adjuvant imatinib for the same group of patients. Nevertheless, controversy over the duration of therapy remains.
Neoadjuvant therapy:
More than half of the new cases of GIST present with advanced or metastatic disease at diagnosis. Strategies that combine the use of imatinib and surgical resection have been tried as the mainstay of treatment for advanced GISTs. Neo-adjuvant therapy is given to improve on the results of surgery. In many patients with large or poorly localized primary tumors that would require extensive surgery or sacrifice a large amount of normal tissue, nee adjuvant imatinib can lead to reduction in tumor size making surgical resection to be safer and to have a better chance of getting a negative margin.
A nonrandomized Phase II trial testing neo-adjuvant/ adjuvant imatinib for primary advanced and potentially operable metastatic I recurrent GIST was carried out by the Radiation Therapy Oncology Group (RTOG). In this study the patients with primary GIST (e"5 cm, group A) or resectable metastatic / recurrent GIST ( e"2 cm, group B) received neo-adjuvant imatinib (600 mg/day) for approximately 2 months and maintenance postoperative imatinib (600 mg/day)for 2 years. Sixtythree patients were originally enrolled (53 analyzable: 31 in group A and 22 in group B). Estimated 5-year progression-free survival and overall survival were 57% in group A, 30% in group B; and 77% in group A, 68% in group B, respectively 38 . Current recommendation is use of preoperative target therapy on a case-bycase basis at centers with experience in the treatment of GIST.
Treatment for locally advanced inoperable disease, metastatic disease and recurrent disease:
lmatinib has been used as a neo adjuvant therapy for down staging a tumor which can later pave the way for surgical resection or as the only available option for locally advanced inoperable disease or metastatic disease or recurrent disease.
Surgery:
Since there is no clear evidence of benefit from initial de-bulking surgery, it is not recommended unless there is an immediate clinical need, such as to remove an obstruction or to stop bleeding 39 . However. Surgery is recommended following maximal tumor response, generally after 3-6 months of neoadjuvant.
Preoperative tumor downstaging therapy:
There are several prerequisites for a successful neoadjuvant therapy or tumor down staging and salvage surgery treatment regimen: -1. An effective treatment, which can shrink the tumor in a significant proportion of patients; 2. A close radiological monitor on the tumor response to the treatment and 3. Repeated assessment by surgeon with a view to carry out curative resection at the right time. Several series reported the experience with preoperative down staging therapy with imatinib at various medical centers 40 .4 1 .4 2 . lmatinib is the preferred initial treatment for patients with locally advanced unresectable disease. One clear message is that salvage surgery following tumor down staging gives good survival outcome and the possibility of a cure in a proportion of patients with unresectable GIST.
lmatinib: lmatinib was tried in an open label, randomized, multicenter trial. One hundred and fortyseven pre-treated patients (98% prior surgery, 51 % prior chemotherapy, and 15% prior radiation therapy) were randomized to receive imatinib 400 mg or 600 mg orally taken once daily. The primary aim was to evaluate the objective response rate of GISTs to imatinib, and the secondary aim was to assess the safety, tolerability, pharmacokinetics, time to treatment failure, and survival. CT or MRI evaluated tumor response. All complete response (CR) or partial responses (PR) were confirmed 4-12 weeks later by a second assessment. 18 FOG-PET scanning was performed to assess possible changes in the metabolic profile of the tumors and in order to compare this imaging technique with standard CT imaging. Analysis of data collected for up to 34 months showed that 84% of patients derived clinical benefit from imatinib therapy, maintaining CR (1 %) or PR (67%) or stable disease (SD; 16%). lmatinib was well tolerated with a low incidence of severe side effects. The 600 mg dose was not significantly more toxic than the 400 mg dose. Following the initiation of imatinib therapy, 80% of the patients (20/25) demonstrated a metabolic response based on evaluation of the PET images. A metabolic response could be observed as early as 24 hours following the administration of a single dose of imatinib. Median time to onset of a CR or PR was 13 weeks 43 . The long-term results of this study showed an almost identical response rates, median progression-free survival and median overall survival in both treatment arms. The median survival was 57 months for all patients. Nearly 50% of patients with advanced GIST treated with imatinib survived for more than 5 years regardless of 400 or 600 mg daily starting dose 44 .
The EORTC performed a dose escalation study over the range of 400 to 1000 mg daily. This established 800 mg daily as the maximum tolerated dose 45 . Phase Ill trials performed both in Europe and Australasia (EORTC 62005 study by EORTC &AGITG) 46 . and in North America (S0033 Intergroup study) 47 . compared imatinib at doses of 400 mg and 800 mg. Apart from confirming the efficacy of imatinib in a larger patient population, a progression-free survival for the 800 mg dose was reported in the larger EORTC study 46 . The improved response and progression-free survival seen in the North American study was not statistically significant 47 . However, a meta-analysis of the combined dataset of 1640 patients has proven that patients with KIT exon 9 mutations have a better outcome if treated at 800 mg daily 48 . Both the phase 111 trials reported that a proportion of patients progressing on imatinib 400 mg daily, who were allowed to crossover to 800 mg daily, experienced response or disease stabilization. In the EORTC study, approximately 30% of patients were still on treatment at 12 months after crossover. 49 Based on these studies, two groups were found to be benefited from the treatment with 400 mg twice daily of imatinib: (1) patients with disease progression on standard-dose therapy, and (2) patients whose tumor harbors an exon 9 mutation in KIT.
The duration of imatinib therapy in advanced GIST has been evaluated in two French Sarcoma Group Phase Ill randomized studies separately evaluating outcomes of patients with responding or stable disease to interruption of treatment after 1 year and after 3 years of imatinib, respectively 50 -51 No differences in overall survival or imatinib resistance were observed between the two arms 50 . In another study, 50 patients with non-progressive disease who had received 3 years of treatment with imatinib were randomly assigned. After a median follow-up of 35 months, 2-year progression-free survival was 80% in the continuation group and 16% in the interruption group 51 .
lmatinib is an effective treatment for unresectable and/ or metastatic GISTs that affect the natural history (time to progression) of the disease. In addition, imatinib increases survival in patients with metastatic and/or unresectable GISTs, in comparison with historical treatment. lmatinib treatment is usually continued indefinitely in the absence of disease progression or unacceptable toxicity, since treatment interruption is generally followed by relatively rapid tumor progression in virtually all patients.
The newer agents
Progression of disease on first line therapy with lmatinib is caused either by initial resistance or more often a secondary mutation in tyrosine kinase KIT or PDGFRA. The standard approach in the case of tumor progression on 400 mg once per day is to increase the imatinib dose to 400 mg twice per day as permitted by toxicity. lmatinib. The median time to tumor progression was 27.3 weeks in patients receiving Sunitinib and 6.4 weeks in those on placebo 55 . A phase II study evaluated whether continuous daily dosing at a lower dose of 37.5 mg per day would be potentially as efficacious and less toxic than the 4/2 schedule. The overall clinical benefit rate was 53% ( 13% experienced partial responses and 40% stable disease). The median progression-free survival was 34 weeks and the median overall survival at the time of analysis was 107 weeks 56 . No new adverse events were apparent compared with the approved intermittent dosing schedule. The results of this study suggest that continuous daily dosing appears to be an effective alternative dosing strategy with acceptable safety for patients. In 2006, the FDA approved second-line use of Sunitinib in patients with advanced GIST who fail (or are intolerant of) imatinib therapy.
Other tyrosine kinase inhibitors have been explored as potential treatments for metastatic or unresectable GIST. These include nilotinib and masatinib.
Nilotinib was recently evaluated in a phase I clinical trial for efficacy 57 . In this trial, 53 patients who had failed prior tyrosine kinase therapies (either imatinib or sunitinib) were randomized to receive nilotinib alone at 400 mg twice a day, nilotinib at 400 mg once a day with imatinib 400 mg twice a day, nilotinib 400 mg twice a day and imatinib 400 mg twice a day, or nilotinib 400 mg twice a day and imatinib 400 mg once a day. The investigators concluded that nilotinib, either in combination with imatinib or alone, were an effective treatment for GIST. 
